These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34206927)

  • 21. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
    Meijer E; Bakker SJ; van der Jagt EJ; Navis G; de Jong PE; Struck J; Gansevoort RT
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):361-8. PubMed ID: 20930090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Fas Ligand, Serum Myostatin and Urine TGF-β1 Are Elevated in Autosomal Dominant Polycystic Kidney Disease Patients with Impaired and Preserved Renal Function.
    Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Sioulis A; Balaskas E; Zebekakis P; Sarafidis PA
    Kidney Blood Press Res; 2018; 43(3):744-754. PubMed ID: 29794429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
    Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
    BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers.
    Sorić Hosman I; Cvitković Roić A; Fištrek Prlić M; Vuković Brinar I; Lamot L
    Front Pediatr; 2023; 11():1274435. PubMed ID: 38027263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
    Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT
    Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease.
    Segarra-Medrano A; Martin M; Agraz I; Vilaprinyó M; Chamoun B; Jatem E; Molina M; Colàs-Campàs L; Garcia-Carrasco A; Roche S
    Clin Kidney J; 2020 Aug; 13(4):607-612. PubMed ID: 32905289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Urinary Neutrophil Gelatinase-Associated Lipocalin for Predicting the Severity of Renal Functions in Patients With Autosomal-Dominant Polycystic Kidney Disease.
    Vareesangthip K; Vareesangthip K; Limwongse C; Reesukumal K
    Transplant Proc; 2017 Jun; 49(5):950-954. PubMed ID: 28583565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensinogen gene polymorphisms and progression of chronic kidney disease in ADPKD patients.
    Gnanasambandan R; Elumalai R; Soundararajan P; Lakkakula BVKS
    Clin Exp Nephrol; 2016 Aug; 20(4):561-568. PubMed ID: 26482465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring urinary biomarkers in autosomal dominant polycystic kidney disease.
    Kawano H; Muto S; Ohmoto Y; Iwata F; Fujiki H; Mori T; Yan L; Horie S
    Clin Exp Nephrol; 2015 Oct; 19(5):968-73. PubMed ID: 25543187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum uromodulin levels, MR imaging findings, and their relationship with eGFR-based CKD staging in ADPKD patients.
    Cansever HN; Sari F; Cevikol C; Cetinkaya R; Süleymanlar G; Ersoy F
    Int Urol Nephrol; 2021 Jul; 53(7):1383-1389. PubMed ID: 33389516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relative Validity of a Beverage Frequency Questionnaire Used to Assess Fluid Intake in the Autosomal Dominant Polycystic Kidney Disease Population.
    Mannix C; Rangan A; Wong A; Zhang J; Allman-Farinelli M; Rangan G
    Nutrients; 2018 Aug; 10(8):. PubMed ID: 30096903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression.
    Piazzon N; Bernet F; Guihard L; Leonhard WN; Urfer S; Firsov D; Chehade H; Vogt B; Piergiovanni S; Peters DJ; Bonny O; Constam DB
    J Transl Med; 2015 Mar; 13():103. PubMed ID: 25888842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease.
    Wang K; Zelnick LR; Chen Y; Hoofnagle AN; Watnick T; Seliger S; Kestenbaum B
    Clin J Am Soc Nephrol; 2020 Jan; 15(1):80-88. PubMed ID: 31628117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Podocyte Injury in Autosomal Dominant Polycystic Kidney Disease.
    Cebeci E; Ekinci I; Gursu M; Coskun C; Karadag S; Uzun S; Behlul A; Senel TE; Kazancioglu R; Ozturk S
    Nephron; 2019; 142(4):311-319. PubMed ID: 31117091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of serum galectin-3 level with renal volume and function in adult polycystic kidney disease.
    Ozkurt S; Dogan I; Ozcan O; Fidan N; Bozaci I; Yilmaz B; Bilgin M
    Int Urol Nephrol; 2019 Jul; 51(7):1191-1197. PubMed ID: 31012038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Copeptin levels and kidney function in ADPKD: case-control study.
    Corradi V; Martino F; Gastaldon F; Scalzotto E; Caprara C; Fortunato A; Pinaffo G; Marchetti C; Fabbi F; Giavarina D; Ferrari F; Rosner MH; Ronco C
    Clin Nephrol; 2016 Sep; 86(9):147-53. PubMed ID: 27487355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urine microRNA as potential biomarkers of autosomal dominant polycystic kidney disease progression: description of miRNA profiles at baseline.
    Ben-Dov IZ; Tan YC; Morozov P; Wilson PD; Rennert H; Blumenfeld JD; Tuschl T
    PLoS One; 2014; 9(1):e86856. PubMed ID: 24489795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
    Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
    PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
    BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.
    Kistler AD; Serra AL; Siwy J; Poster D; Krauer F; Torres VE; Mrug M; Grantham JJ; Bae KT; Bost JE; Mullen W; Wüthrich RP; Mischak H; Chapman AB
    PLoS One; 2013; 8(1):e53016. PubMed ID: 23326375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.